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Exome Sequencing Identifies INPPL1 Mutations
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Opsismodysplasia (OPS) is a severe autosomal-recessive chondrodysplasia characterized by pre- and postnatalmicromelia with extremely
short hands and feet. The main radiological features are severe platyspondyly, squared metacarpals, delayed skeletal ossification,
and metaphyseal cupping. In order to identify mutations causing OPS, a total of 16 cases (7 terminated pregnancies and 9 postnatal
cases) from 10 unrelated families were included in this study. We performed exome sequencing in three cases from three unrelated
families and only one gene was found to harbor mutations in all three cases: inositol polyphosphate phosphatase-like 1 (INPPL1).
Screening INPPL1 in the remaining cases identified a total of 12 distinct INPPL1mutations in the 10 families, present at the homozygote
state in 7 consanguinous families and at the compound heterozygote state in the 3 remaining families. Most mutations (6/12) resulted
in premature stop codons, 2/12 were splice site, and 4/12 were missense mutations located in the catalytic domain, 5-phosphatase.
INPPL1 belongs to the inositol-1,4,5-trisphosphate 5-phosphatase family, a family of signal-modulating enzymes that govern a plethora
of cellular functions by regulating the levels of specific phosphoinositides. Our finding of INPPL1 mutations in OPS, a severe spondy-
lodysplastic dysplasia with major growth plate disorganization, supports a key and specific role of this enzyme in endochondral
ossification.Opsismodysplasia (OPS [MIM 258480]) is a rare chondro-
dysplasia, first described in 1977 by Zonana et al.1 and
coined as ‘‘opsismodysplasia’’ (from ‘‘opsismos,’’ Greek
for ‘‘late’’) by Maroteaux et al. in 1984.2,3 To date, 30 cases
have been reported and recurrence in sibs and/or consan-
guinity have suggested an autosomal-recessive mode of
inheritance.4 The disorder is characterized by pre- and
postnatal micromelia with extremely short hands and
feet. The main radiological features are severe platyspon-
dyly, squared metacarpals, major delay in skeletal ossifica-
tion, and metaphyseal cupping. The outcome is more
variable than initially thought, ranging from severe
prenatal findings to late survival.4
In the international nosology for skeletal dysplasias,5
OPS belongs to the group of severe spondylodysplastic
dysplasias (group 14). This group also includes (1) achon-
drogenesis type 1A (ACG1A [MIM 200600]) due to TRIPP11
mutations (MIM 604505) and distinct by poor ossifica-
tion of vertebral bodies and skull, (2) Schneckenbecken
dysplasia (MIM 296250) due to SLC35D1 mutations
(MIM 610804) and characterized by a snail-like appearance
of the ilia, (3) spondylometaphyseal dysplasia (SMD)
Sedaghatian type (MIM 250220), a less severe condition,
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ular basis of which remains unknown.
In order to identify the mutations causing OPS, a total
of 16 cases from 10 unrelated families were included in
this study. Among them, seven were terminated pregnan-
cies (14–29 weeks of gestation) and nine were postnatal
cases (birth to 19 years). Recurrency was observed in 5/
10 families and consanguinity in 7/10. Inclusion criteria
were (1) major delay in epiphyseal ossification, (2) platy-
spondyly, (3) metaphyseal cupping, and (4) very short
metacarpals and phalanges (Figure 1). The clinical details
are summarized in Table 1. Histological study of the
femoral growth plate performed in the three cases from
family 5 and in the prenatal case from family 3 (Table 1)
showed similar disorganization of the growth plate with
absence of columnar arrangement of proliferative cells
and reduced hypertrophic zone with small number of
hypertrophic chondrocytes (Figure 1A, III and IV). In
two postnatal cases (Table 1, families 3 and 7), the phos-
phocalcic work up was normal (including blood levels of
creatinine, calcium, phosphorus, thyroxin, thyrotropin,
25-hydroxyvitaminD, 1,25-dihydroxyvitaminD, parathy-
roid hormone, and urinary levels of creatinine, calcium,
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Figure 1. Clinical, Radiological, and His-
tological Features of OPS Cases
(A) Antenatal radiological and histological
features in two OPS cases from family 5.
Skeleton X-rays (I, II) in case 1 showing
hypoplastic vertebral bodies, very short
metacarpals, horizontal acetabular roof,
and metaphyseal irregularities. Growth
plate study at the femoral head in sib 2
(15 WG, III) showing nearly absent
columnar organization and reduced
hypertrophic zone (HY zone) with small
reduced number of hypertrophic chondro-
cytes compared to wild-type growth plate
(15 WG, IV).
(B) Clinical and radiological findings in
case 1 (family 3) at 4 years (I, II, IV, V, VII)
and 2 years (III, VI) showing lower limb
valgus deformity (I), extremely short
hands (II), shortmetacarpalwithmetaphy-
seal cupping and dysplastic carpal ossifica-
tion (III, IV), severe epiphyseal delay and
metaphyseal cupping around the knee
(V), and severe platyspondyly (VI, VII).Informed consent for participation and sample collec-
tion were obtained by protocols approved by the Necker
Hospital ethics board committee. We first excluded the
genes involved in the lethal spondylodysplastic group by
direct sequencing, namely SBDS (MIM 607444) involved
in some cases of spondylometaphyseal dysplasia Sedhaga-
tian type,6 SLC35D1,7 and TRIP11.8 We then decided to
undertake an exome capture-sequencing in three OPS
cases from families 1–3.
Exome capture was performed at the French National
Sequencing Institute (CNG) with the SureSelect Human
All Exon kit (Agilent Technologies).9 Single-end se-
quencing was performed on an Illumina Genome Analyzer
IIx (Illumina), generating 72-base reads. For sequence
alignment, variant calling, and annotation, the sequences
were aligned to the human genome reference sequence
(hg18 build), via BWA aligner.10 Downstream processing
was carried out with the Genome Analysis Toolkit
(GATK),11 SAMtools,12 and Picard Tools. Substitution calls
were made with GATK Unified Genotyper, whereas indel
calls were made with a GATK IndelGenotyperV2. All calls
with a read coverage%23 and a Phred-scaled SNP quality
of %20 were filtered out. All the variants were annotated
with an in-house developed annotation software system.
We first focused our analyses on nonsynonymous variants,
splice acceptor and donor site mutations, and coding
indels, anticipating that synonymous variants were far
less likely to be disease causing (Table S1 available online).
We also defined variants as previously unidentified if they
were absent from both control populations and data sets
including dbSNP129, the 1000 Genomes Project, and in-
house exome data.
Based on the recessive mode of inheritance of OPS, only
one gene was found to harbor mutations in all three
cases (Table S1) and was therefore selected. This gene,
inositol polyphosphate phosphatase-like 1 (INPPL1), isThe Americalso referred to as SHIP2, for SH2 (Src homology 2)-
domain-containing inositol phosphatase (MIM 600829).
Indeed, exome analysis detected five INPPL1 mutations in
the three individuals and was present at the homozygote
state in case 1 and compound heterozygote state in cases 2
and 3. These results were confirmed by Sanger sequencing.
INPPL1 (RefSeq accession number NM_001567.3) is
composed of 28 coding exons and encodes a protein of
1,258 amino acids characterized by a N-terminal SH2
domain, a conserved catalytic 5-phosphatase domain,
a C-terminal proline-rich region with consensus sites for
SH3 domain interactions, a ubiquitin interacting motif,
and a sterile alpha motif (SAM) (Figure 2). Subsequent
screening of the 28 INPPL1 coding exons in the remaining
cases led to identification of seven additional mutations.
Altogether, we identified a total of 12 distinct INPPL1
mutations in the 10 families (Figure 2, Table 2). Among
them, 2/12 were nonsense mutations (c.2845C>T
[p.Arg949*], c.2719C>T [p.Arg907*]) and 4/12 were
frameshift mutations (c.276_280del [p.Gln93Profs*3],
c.1845dupT [p.Ile616Tyrfs*14], c.94_121del [p.Glu32-
Metfs*77], c.1328delinsTA [p.Thr443Ilefs*23]) located in
regions encoding the SH3 binding, SH2, or 5-phosphatase
domains. They were expected to result in a truncated
protein with no prolin-rich and SAM domains, which are
crucial for protein-protein interaction. In addition, 2/12
were splice-site mutations (c.5193A>G, c.1951þ1G>A).
Alamut Splicing Predictions, via bioinformatic analysis
SSF,MaxEnt, NNSPLICE, andHSF, predicted a new acceptor
site in c.5192, generating a frameshift of two additional
bases followed by a premature stop codon, and the suppres-
sionof thedonor site in c.1951, generating apremature stop
codon. Finally, 4/12 were missense mutations (c.1975C>T
[p.Pro659Ser], c.1201C>T [p.Arg401Trp], c.2164T>A
[p.Phe722Ile], c.2064G>T [p.Trp688Lys]) located in the 5-
phosphatase domain. These mutations cosegregated withan Journal of Human Genetics 92, 144–149, January 10, 2013 145
Table 1. Clinical Features of the Ten OPS Families
Ethnic Origin CS Prenatal Findings
Parameters
at Birth Facial Features
Respiratory
Insufficiency
Short Hand,
Feet Other Outcome
Family 1, Sib 1 Arab Moslem 1st cousin short long bones
(25 WG)
W 2,700 g;
L 41.5 cm;
HC 32.5 cm
hypertelorism, high
forehead, short nose, long
philtrum, large fontanelle
– yes – died at 15 months
Family 1, Sib 2 Arab Moslem 1st cousin short long bones ? ? – yes – termination of
pregnancy
Family 2 (male) Somalian no ? ? coarse face, hypertelorism,
high forehead, short
nose, large fontanelle
lung infections yes – 4 years old; L,
W%5 SD, HC P3
Family 3, Sib 1
(male)
French/Algerian no ureteral dilatation W 3,400 g;
L 49 cm;
HC 36 cm
coarse face, high forehead,
short nose, long philtrum,
large fontanelle
– yes paraplegia after
surgery for scoliosis
19 years old;
H 140 cm; W 36 kg
Family 3, Sib 2
(male)
French/Algerian no polyhydramnios,
short femora (22 WG),
narrow thorax, short
hands, feet
W 440 g;
L 19.5 cm
(22 WG)
high forehead, short nose lung hypoplasia yes – termination of
pregnancy (22 WG)
Family 4 (male) Portuguese 1st cousin short limbs W 3,300 g;
L 45 cm;
HC 38 cm
hypertelorism, frontal
bossing, short nose, long
philtrum, macrostomia,
wide fontanelle
yes; narrow
thorax
yes cervical kyphosis,
scoliosis
19 years
Family 5, Sib 1
(male)
French no short limbs (24 WG),
short hands, narrow
thorax
W 1,280 g;
L 33 cm;
HC 29 cm
(29 WG)
coarse face, high forehead,
short nose, long philtrum
pulmonary
hypoplasia
yes – termination of
pregnancy (29 WG)
Family 5, Sib 2
(female)
French no hygroma, short
limbs (14 WG),
narrow thorax
W 30 g;
L 9.5 cm
(15 WG)
– – – – termination of
pregnancy (15 WG)
Family 5, Sib 3
(female)
French no hygroma, narrow
thorax, short limbs
W 40 g;
L 8.5 cm
(14 WG)
– – – – termination of
pregnancy (14 WG)
Family 6 (male) Arab (Saudi) 1st cousin short limbs ? hypertelorism, midface
hypoplasia, wide
fontanelle, broad forehead
chronic lung
disease
yes tricuspide and mitral
valve prolapse
3.5 years old
Family 7 (male) Algerian 2nd cousin – W 3120 g;
L 34 cm;
HC 34 cm
high forehead, short nose
with anteverted nares
– yes scoliosis, lower limb
varus deformity
9 years old; H 115 cm
(%4 SD); W 24.9 kg;
HC 55.5 cm
Family 8, Sib 1
(female)
French no short femora (24 W),
short hands, narrow
thorax
W 1,400 g;
L 29 cm;
HC 31 cm
coarse face, high forehead,
short nose
pulmonary
hypoplasia
yes – termination of
pregnancy (29 WG)
Family 8, Sib2
(female)
French no hygroma, IUGR L 9 cm
(15 WG)
– – yes – termination of
pregnancy (15 WG)
(Continued on next page)
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Figure 2. Localization of INPPL1 Mutations Identified in OPS
Individuals
The Americthe disease, were present at the heterozygote state in the
parents, were considered as pathogenic in the PolyPhen
and Sift database, and were absent from alleles in 200
ethnicity-matched controls.
Here, we report INPPL1mutations in ten unrelated fami-
lies of opsismodysplasia. All cases clearly fulfilled the diag-
nostic criteria for OPS but were variable in severity. Indeed,
prenatal findings detected in four families led to early
termination of pregnancies (especially in recurrent sibs)
in 7/16 cases and hygroma, short long bones, short ex-
tremities, and narrow thorax were consistently observed.
Four children died early (stillborn at 30 weeks of gestation
to 15 months of age). The five remaining cases ranged in
age from 3 to 19 years old and had normal cognitive devel-
opment, severe short stature (<4 SDS), lower limb defor-
mity, and severe scoliosis with atlanto axial instability (at
least in one case).
Mostmutations (6/12) resulted inpremature stopcodons,
2/12 were splice-site mutations, and 4/12 were missense
mutations located in the catalytic domain, 5-phosphatase,
presumably responsible for impaired catalytic activity.
INPPL1 belongs to the inositol-1,4,5-trisphosphate
5-phosphatase family, a family of signal-modulating
enzymes that govern a plethora of cellular functions by
regulating the levels of specific phosphoinositides. Growth
factor or insulin stimulation induces a canonical cascade
resulting in the transient phosphorylation of phosphatidy-
linositol (PtdIns) (4,5)P(2) by PI3K (phosphoinositide
3-kinase) to form PtdIns(3,4,5)P(3), which is rapidly de-
phosphorylated either by phosphatase and tensin
homolog (PTEN) back to PtdIns(4,5)P(2) or by the inositol
polyphosphate 5-phosphatases (5-ptases) generating
PtdIns(3,4)P(2). Ten mammalian 5-ptases have been iden-
tified. Their gene-targeted deletion in mice has revealed
that these enzymes regulate haemopoietic cell prolifera-
tion, synaptic vesicle recycling, insulin signaling, endocy-
tosis, vesicular trafficking, and actin polymerization.13
More specifically, INPPL1 has been implicated in the nega-
tive regulation of insulin signaling and glucose homeo-
stasis in specific tissues.14 SNP analysis in the Japanese
population have suggested that INPPL1 polymorphismsan Journal of Human Genetics 92, 144–149, January 10, 2013 147
Table 2. INPPL1 Mutations in Families in Opsismodyplasia
Family Ethnic Origin CS
No. of Affected
Children
Nucleotide
Change Status
Amino Acid
Change Location Domain
1 Arab Moslem yes 2 c.2845C>T/ ho p.Arg949* Ex25 SH3 binding domain
2 Somalian no 1 c.276_280del he p.Gln93Profs*3 Ex3 SH2 domain
c.1975C>T he p.Pro659Ser Ex17 5phophatase domain
3 French/Algerian no 2 c.1201C>T he p.Arg401Trp Ex11 5phophatase domain
c.2164T>A he p.Phe722Ile Ex19 5phophatase domain
4 Portuguese yes 1 c.2719C>T ho p.Arg907* Ex24 /
5 French yes 3 c.1845dupT ho p.Ile616Tyrfs*14 Ex15 5phophatase domain
6 Arab (Saudi) yes 1 c.519-3A>G ho ? In4 /
7 Algerian yes 1 c.1951þ1G>A ho ? In16 /
8 French no 2 c.1328delinsTA
c.2064G>T
he
he
p.Thr443Ilefs*23
p.Trp688Lys
Ex12
Ex18
5phophatase domain
5phophatase domain
9 Brazil yes 1 c.94_121del ho p.Glu32Metfs*77 Ex1 SH2 domain
10 Brazil yes 2 c.94_121del ho p.Glu32Metfs*77 Ex1 SH2 domain
Abbreviations are as follows: Cs, consanguinity; ho, homozygote; he, heterozygote; /, mutation not localized in a known protein domain.are associated with a predisposition to insulin resistance.15
Moreover, animal models lacking Inppl1 had increased
glucose intolerance and insulin sensitivity. However,
Inppl1/ mice were viable and had normal glucose and
insulin levels but were highly resistant to weight gain,
suggesting that Inppl1 mediates obesity resistance.16 In
the four survivors from our series, no insulin resistance
was reported and length and weight were both %4 SD.
Recent studies have suggested additional noncatalytic
properties of INPPL1 that may act as a docking protein for
a large number of proteins including cytoskeletal, focal
adhesion, or scaffold proteins, phosphatases, and tyrosine
kinase-associated receptors, like EGF receptor. Moreover,
loss of INPPL1 in zebrafish led to an increased andexpanded
expression of outputs of FGF-mediated signaling.13
The finding of INPPL1 mutations in OPS, a severe spon-
dylodysplastic dysplasia with major growth plate disorga-
nization, supports a key and specific role of this enzyme
in the endochondral ossification process, through either
its role in postranslational modifications (phosphorylation
or ubiquitination) or its interaction with specific protein
network. We conclude that INPPL1 mutations are respon-
sible for OPS. Ongoing studies will hopefully lead to an
understanding of the specific role of this enzyme in the
ossification process.Supplemental Data
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